---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-23-071272"
form_type: "8-K"
ticker: "BJDX"
cik: "0001704287"
company_name: "Bluejay Diagnostics, Inc."
filed_at: "2023-08-28T23:59:59+00:00"
generated_at: "2026-06-11T02:54:50.074284+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Bluejay Diagnostics announces $1.59M registered direct offering and warrant private placement

## Summary
- Company entered definitive agreement for registered direct offering of 216,000 shares at $7.365/share, raising ~$1.59M gross.
- Concurrent private placement of warrants to purchase 216,000 shares at $7.24/share, exercisable for 5 years.
- Proceeds intended for FDA approval activities, clinical studies, R&D, and general working capital.
- H.C. Wainwright & Co. acted as exclusive placement agent; closing expected August 28, 2023.
- Warrants and underlying shares sold unregistered under Section 4(a)(2) and Regulation D.

## SEC filing metadata
- accession: 0001213900-23-071272
- form_type: 8-K
- ticker: BJDX
- cik: 0001704287
- company_name: Bluejay Diagnostics, Inc.
- filed_at: 2023-08-28T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 1.01, 3.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1704287/000121390023071272/0001213900-23-071272-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1704287/000121390023071272/ea184305-8k_bluejay.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-23-071272
- JSON: https://secwatch.observer/filing/0001213900-23-071272.json
- Plain text: https://secwatch.observer/filing/0001213900-23-071272.txt

## Key facts
- Material Agreements
  Bluejay Diagnostics, Inc. entered into Purchase Agreement with certain institutional and accredited investors valued at approximately $1.59 million (effective 2023-08-24).
  - Action: entry
  - Agreement: equity purchase
  - Counterparty: certain institutional and accredited investors
  - Value: approximately $1.59 million
  - Effective: 2023-08-24
  source text: On August 24, 2023, Bluejay Diagnostics, Inc. (the “Company”) entered into a securities purchase agreement with certain institutional and accredited investors (the “Purchase Agreement”) relating to the registered direct offering and sale of 216,000 shares of the Company’s common stock
  evidence_url: https://www.sec.gov/Archives/edgar/data/1704287/000121390023071272/0001213900-23-071272-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.